SB1230 amends Arizona law governing the medical marijuana fund and the Arizona biomedical research centre to create and finance competitive grants for marijuana clinical trials. The bill directs the centre to fund FDA-approved trials that evaluate the safety and efficacy of marijuana in humans and study marijuana’s interactions with prescription, nonprescription, and illicit drugs. It also requires that the trials be conducted by Arizona-based researchers affiliated with nonprofit organizations or universities, and that they receive approval from the FDA, DEA, and an institutional review board, with results suitable for publication in peer-reviewed medical and public health journals.
The bill prioritizes randomized controlled clinical trials focused on autism, epilepsy, post-traumatic stress disorder, and pain. It also provides a limited legal protection for grant recipients and their employees by barring prosecution for possession of marijuana cultivated for medical use while they are working on the clinical trial. In addition, the bill sets funding parameters from the medical marijuana fund, including up to $2 million annually beginning by July 1, 2026 for five consecutive years, and an additional $2 million by July 1, 2028 if the fund is financially stable and not at risk of deficit or fee increases. Administrative costs are capped at five percent.
The bill would change state law by expanding the authorized use of the medical marijuana fund beyond existing purposes to support clinical research infrastructure and trial grants, while also creating a narrow immunity from prosecution tied to approved research activity. It affects the Arizona biomedical research centre, the Department of Health Services, researchers, universities, nonprofit organizations, and participants in marijuana clinical trials. Because the measure amends a statute related to medical marijuana funding and criminal liability, it also includes a three-fourths vote requirement for enactment.
Overall, the bill appears to have received mixed but generally workable support in committee, with stronger support in the Senate than in the House. It passed the Senate floor 23-6, but the House third reading vote was much closer to defeat at 13-39, indicating substantial opposition in the House despite earlier committee approvals. The committee votes suggest the bill was acceptable to many members as a research and public health measure, but not broadly supported enough to clear the House.
The main points of contention appear to be the use of medical marijuana fund dollars for research grants, the scope of legal protections for researchers handling marijuana, and whether the state should prioritize these clinical trials over other uses of the fund. Supporters likely viewed the bill as a way to advance evidence-based research on marijuana and potential therapeutic uses, while opponents may have objected to the funding commitment, the marijuana-related criminal immunity, or the policy implications of expanding state involvement in cannabis research.
SB1230 would amend A.R.S. § 36-2822 to authorize the Arizona biomedical research centre to distribute medical marijuana fund dollars as competitive grants for FDA-approved marijuana clinical trials, with specific eligibility, approval, and publication requirements. It also creates a narrow immunity from prosecution for grant recipients and their employees while they are working on approved trials involving cultivated medical marijuana. The bill reallocates fund resources for research administration and grants, caps administrative spending at five percent, and conditions an additional funding tranche on the fund’s financial stability.
The bill’s sentiment appears cautiously favorable in the Senate and more divided in the House. It advanced through Senate committees and passed the Senate floor by a solid margin, suggesting meaningful support for marijuana-related medical research. In the House, however, committee votes were closer and the final third-reading vote was overwhelmingly negative, indicating that support weakened substantially or that opposition coalesced late in the process.
The most notable contention centers on whether medical marijuana fund revenues should be used to finance clinical trials and whether the state should grant legal protections to researchers handling marijuana. Opponents likely objected to the fiscal commitment, the policy choice to prioritize cannabis research, and the immunity from prosecution, while supporters emphasized FDA-approved, university- and nonprofit-based research into autism, epilepsy, PTSD, pain, and drug interactions. The House floor vote suggests these concerns were significant enough to prevent passage despite earlier committee approval.